Allaying the fears: Midomafetamine with therapy is a medicine

Abstract

Get full access to this article

View all access options for this article.

References

Van den Brink W Report of the Dutch State Committee on MDMA: A summary of findings and recommendations (2024) https://www.drugscience.org.uk/mdma-netherlands-report

APA (2019) FDA approves novel depression treatments. https://www.psychiatry.org/news-room/apa-blogs/fda-approves-novel-depression-treatment.

Berman

Cappiello

Anand

, et al. (2000 Feb 15) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47(4): 351–354. doi: 10.1016/s0006-3223(99)00230-9. PMID: 10686270.

Bonomo

Norman

Biondo

, et al. (2019 Jul) The Australian drug harms ranking study. Journal of Psychopharmacology 33(7): 759–768. doi: 10.1177/0269881119841569. Epub 2019 May 13. Erratum in: J Psychopharmacol. 2019 Nov;33(11):1471. doi: 10.1177/0269881119877724. PMID: 31081439.

Carhart-Harris

Bolstridge

Rucker

, et al. (2016 Jul) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry 3(7): 619–627. doi: 10.1016/S2215-0366(16)30065-7.

Crossin

Cleland

Wilkins

, et al. (2023 Sep) The NewZealand drug harms ranking study: A multi-criteria decisionanalysis. Journal of Psychopharmacology 37(9): 891–903. DOI: https://doi.org/10.1177/02698811231182012.

Donauer

(2022) Legal framework for the use of psychedelics in Switzerland. Life Sciences &Healthcare. https://www.mll-news.com/legal-framework-for-the-use-of-psychedelics-in-switzerland/?lang=en

EMA (2013) https://www.ema.europa.eu/en/medicines/human/EPAR/selincro .

FDA (2019) https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certifiedx .

10.

Foa

McLean

(2016) The efficacy of exposure therapy for anxiety-related disorders and its underlying mechanisms: The case of OCD and PTSD. Annual Review of Clinical Psychology 12: 1–28. doi: 10.1146/annurev-clinpsy-021815-093533. Epub 2015 Nov 11. PMID: 26565122.

11.

Ford

Grasso

Greene

, et al. (2018 Sep) Randomized clinical trial pilot study of prolonged exposure versus present centred affect regulation therapy for PTSD and anger problems with male military combat veterans. Clinical Psychology & Psychotherapy 25(5): 641–649. doi: 10.1002/cpp.2194. Epub 2018 Apr 23. PMID: 29687524.

12.

Global Drug Survey (GDS) (2020) https://www.globaldrugsurvey.com/gds-2020/gds-2020-mdma-not-just-about-the-dose-but-how-you-divide-it-or-not/.

13.

Grabski

McAndrew

Lawn

, et al. (2022 Feb) Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. American Journal of Psychiatry 179(2): 152–162. doi: 10.1176/appi.ajp.2021.21030277. Epub 2022 Jan 11. PMID: 35012326.

14.

History (2022) How AIDS activists fought for patients’ rights. https://www.history.com/news/act-up-aids-patient-rights.

15.

Hoskins

Pearce

Bethell

, et al. (2015) Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. British Journal of Psychiatry 206(2): 93–100.

16.

Hunt

(2023) Draft Clinical Memorandum on the Therapeutic Use of MDMA for PTSD and Psilocybin for Treatment Resistant Depression.

17.

ICER (2024) Draft evidence report on treatment for post-traumatic stress disorder. ICER. https://icer.org/wp-content/uploads/2024/03/PTSD_Draft-Report_For-Publication_03262024.pdf.

18.

Jerome

Feduccia

Wang

, et al. (2020 Aug) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl) 237(8): 2485–2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PMID: 32500209; PMCID: PMC7351848.

19.

Keller

McCullough

Klein

, et al. (2000 May 18) A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic xdepression. New England Journal of Medicine 342(20): 1462–1470. doi: 10.1056/NEJM200005183422001. Erratum in: N Engl J Med 2001 Jul 19;345(3):232. PMID: 1081618.

20.

Knight

(2003) Agony for researchers as mix-up forces retraction of ecstasy study. Nature 425: 109. https://doi.org/10.1038/425109a.

21.

Krupitsky

Grinenko

(1997 Apr-Jun) Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs 29(2): 165–183. doi: 10.1080/02791072.1997.10400185. PMID: 9250944.

22.

Mitchell

Ot'alora

van der Kolk

, et al. MAPP2 Study Collaborator Group. (2023 Oct) MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine 29(10): 2473–2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14. PMID: 37709999; PMCID: PMC10579091.

23.

Mitchell

Bogenschutz

Lilienstein

, et al. (2021 Jun) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27(6): 1025–1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PMID: 33972795; PMCID: PMC8205851.

24.

Mithoefer

Feduccia

Jerome

, et al. (2019 Sep) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl) 236(9): 2735–2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PMID: 31065731; PMCID: PMC6695343.

25.

Mithoefer

Wagner

Mithoefer

, et al. (2013 Jan) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology 27(1): 28–39. doi: 10.1177/0269881112456611. Epub 2012 Nov 20. PMID: 23172889; PMCID: PMC3573678.

26.

Mt-Isa

Hallgreen

Wang

, et al. (2014 Jul) Ashby D; IMI-PROTECT benefit-risk participants. Balancing benefit and risk of medicines: A systematic review and classification of available methodologies. Pharmacoepidemiology and Drug Safety 23(7): 667–678. doi: 10.1002/pds.3636. Epub 2014 May 13. PMID: 24821575.

27.

Nicholas

Wang

Coker

, et al. (2022 Apr 1) The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug and Alcohol Dependence 233: 109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID: 35286849; PMCID: PMC9750500.

28.

NIDA (2024) https://nida.nih.gov/research-topics/mdma-ecstasy-molly#work .

29.

Nutt

Crome

Young

(2024 May 20) Is it now time to prepare psychiatry for a psychedelic future? British Journal of Psychiatry: 1–3. doi: 10.1192/bjp.2024.76. Epub ahead of print. PMID: 38764044. doi:https://doi.org/10.1192/bjp.2024.76

30.

Nutt

De Wit

(2021) Putting the MD back intoMDMA. Nature Medicine 27(6): 950–951. DOI: https://doi.org/10.1038/s41591-021-01385-8..

31.

Nutt

King

Phillips

(2010 Nov 6) Drug harms in the UK: A multicriteriadecision analysis. Lancet 376(9752): 1558–1565. DOI: https://doi.org/10.1016/S0140-6736(10)61462-6.

32.

Nutt

Sharpe

(2008 Jan) Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. Journal of Psychopharmacology 22(1): 3–6. doi: 10.1177/0269881107086283. PMID: 18187527.

33.

Office for National Statistics (ONS) (2023) https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2023#frequency-of-drug-use-in-the-last-year

34.

Oreskes and Conway (2010) https://en.wikipedia.org/wiki/Merchants_of_Doubt

35.

Otto

Tolin

Simon

, et al. (2010 Feb 15) Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry 67(4): 365–370. doi: 10.1016/j.biopsych.2009.07.036. Epub 2009 Oct 6. PMID: 19811776.

36.

Phillips

Fasolo

Zafiropoulos

, et al. (2011) Is quantitative benefit-risk modelling of drugs desirable or possible? Drug Discovery Today: Technologies 8(1): e3–e10.

37.

RANZCP. Use of ketamine in psychiatric practise 2022. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/use-of-ketamine-in-psychiatric-practice.

38.

Schneier

Neria

Pavlicova

, et al. (2012 Jan) Combined prolonged exposure therapy and paroxetine for PTSD related to the world trade center attack: A randomized controlled trial. American Journal of Psychiatry 169(1): 80–88. doi: 10.1176/appi.ajp.2011.11020321. Epub 2011 Sep 9. PMID: 21908494; PMCID: PMC3606709.

39.

Sessa

Higbed

O'Brien

, et al. (2021 Apr) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology 35(4): 375–383. doi: 10.1177/0269881121991792. Epub 2021 Feb 18. PMID: 33601929.

40.

Szigeti

Heifets

(2024 May) Expectancy effects in psychedelic trials. Biological Psychiatry 9(5): 512–521. doi: 10.1016/j.bpsc.2024.02.004. Epub 2024 Feb 20. PMID: 38387698.

41.

Szigeti

Weiss

Rosas

, et al. (2024 Jun) Assessing expectancy and suggestibility in a trial of escitalopram v. Psilocybin for depression. Psychological Medicine 54(8): 1717–1724. doi: 10.1017/S0033291723003653. Epub 2024 Jan 22. PMID: 38247730.

42.

Tuerk

Wangelin

Powers

, et al. (2018 Sep) Augmenting treatment efficiency in exposure therapy for PTSD: A randomized double-blind placebo-controlled trial of yohimbine HCl. Cognitive Behaviour Therapy 47(5): 351–371. doi: 10.1080/16506073.2018.1432679. Epub 2018 Feb 15. PMID: 29448886.

43.

van Amsterdam

Nutt

Phillips

, et al. (2015 Jun) European rating of drug harms. Journal of Psychopharmacology 29(6): 655–660. doi: 10.1177/0269881115581980. Epub 2015 Apr 28. PMID: 25922421.

44.

Van den Brink

(2020) Report of the Dutch State Committee on MDMA: A summary of findings and recommendations. https://www.drugscience.org.uk/mdma-netherlands-report.